FASLODEX sol inj 250 mg/5ml 2 ser pré 5 ml
7680567780121
CH-56778
L02BA03
07.16.2.
Reimbursement limitations:
FASLODEX
Traitements des patientes à la post-ménopause (ménopause naturelle ou induite) avec cancer du sein localement …
1 / 3
google
Details
- Product number
- 5677801
- CPT
- -
- Packaging group
- 2
- Unit
- Spritze(n)
- Composition
- fulvestrantum 250 mg, ethanolum 96 per centum 500 mg, alcohol benzylicus 500 mg, benzylis benzoas 750 mg, ricini oleum virginale q.s. ad solutionem pro 5 ml corresp., ethanolum 12 % V/V.
Articles (1)
Faslodex, Injektionslösung
Injektionslösung
2
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
250.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
500.0 MG | Substance | HBESI |
|
(N/A)
|
500.0 MG | Substance | HBESI |
|
(N/A)
|
750.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
12.0 PVV | Substance | HNIDK |
Reimbursement information
Public price
CHF 379.80
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2011
Authorization holder
AstraZeneca AG
6340 Baar
Authorization information
- Swissmedic authorization number
- 56778
- Drug name
- Faslodex, Injektionslösung
- Galenic form
- LSINJ
- ATC Code
- L02BA03
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 19/03/2004
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.2.
- Domain
- Human medicine
Packaging details
- Description (FR)
- FASLODEX sol inj 250 mg/5ml 2 ser pré 5 ml
- Description (DE)
- FASLODEX Inj Lös 250 mg/5ml 2 Fertspr 5 ml
- Market launch
- 19/03/2004
- Narcotic (BTM)
- No